Meta Category: Healthcare

Key Highlights

  • Optiscan has submitted a US FDA 510(k) application for its InVue precision surgery device.
  • The filing follows the recently announced 510(k) submission for the company’s InForm digital pathology device.
  • InVue is designed to provide microscopic cellular-level imaging directly in the operating theatre.
  • Optiscan is progressing clinical reference sites, customer engagement, Manufacturing scale-up and partner discussions in parallel with review.

Optiscan Imaging Limited (ASX:OIL) has lodged its InVue precision surgery device with the US Food and Drug Administration under the 510(k) pathway, moving the platform into formal regulatory review. The filing follows Optiscan’s recent submission for InForm and brings a second device into the US clearance process. InVue is intended to deliver microscopic, cellular-level imaging during surgery, allowing clinicians to examine tissue at the point where operative decisions are being made.

InVue Moves From Development to Independent Review

The 510(k) submission follows engineering, clinical validation, external testing and regulatory preparation. FDA reviewers will assess whether the device meets the requirements of the pathway. Clearance would be required before Optiscan can pursue commercial rollout in the United States for the cleared indications, making the regulatory review a defined gate between development and market entry.

Real-Time Imaging Defines the Product Proposition

InVue was unveiled in June 2024 as a next-generation microscopic medical imaging system for use in surgery. The device is designed to provide cellular-level visualisation in real time rather than relying solely on tissue removal and later pathology. Optiscan identifies surgical oncology as an initial target because intraoperative decisions can depend on rapid information about tissue characteristics.

Commercial Preparation Runs Beside Regulation

While the FDA reviews the application, Optiscan plans to continue building clinical reference sites, engaging prospective customers, scaling manufacturing and holding discussions with commercial partners. This parallel approach is intended to reduce the gap between any future clearance and market readiness, although commercial launch remains conditional on regulatory outcome.

FDA Submission Is Not FDA Clearance

A completed 510(k) application does not guarantee authorisation. Regulators may request additional information, and review timing can vary. Even after clearance, adoption would depend on clinical workflow integration, purchasing decisions, reimbursement considerations, manufacturing capacity and the company’s ability to establish an effective US commercial channel.

Forward-Looking Summary

Optiscan now awaits the FDA review process while continuing manufacturing and market-preparation activities intended to support a potential US launch if InVue receives clearance.